-1753896155030.webp&w=3840&q=75)
2025 NOSCM | Clinical Challenges in the Management of Thrombosis and Acquired Inhibitors in Cancer Patients
Overview
Dr. Ewa Wysokinska discussed how thrombosis affects 20% of cancer patients, especially in GI, ovarian, brain, and renal cancers. DOACs like apixaban are effective with lower bleeding risk vs. heparin. Extended low-dose apixaban is safe. The Khorana score aids risk prediction. Acquired inhibitors need targeted therapy and cancer control.
Target Audience
Physicians
Nurses
Pharmacists
Physician Associates
This material is non‑CME, no credits are available, and a certificate will not be provided upon completion.
Faculty
Ewa Wysokinska, MD
Date of Release
July 30th, 2025
-1755991489210.webp&w=3840&q=75)
-1755991393648.webp&w=3840&q=75)